DK1233782T3 - Fremkaldelse af HCV-specifikke antistoffer - Google Patents

Fremkaldelse af HCV-specifikke antistoffer

Info

Publication number
DK1233782T3
DK1233782T3 DK00993586T DK00993586T DK1233782T3 DK 1233782 T3 DK1233782 T3 DK 1233782T3 DK 00993586 T DK00993586 T DK 00993586T DK 00993586 T DK00993586 T DK 00993586T DK 1233782 T3 DK1233782 T3 DK 1233782T3
Authority
DK
Denmark
Prior art keywords
hcv
antibodies
induction
specific antibodies
nob
Prior art date
Application number
DK00993586T
Other languages
English (en)
Inventor
Michael Houghton
Mark Selby
Sergio Abrignani
Jens Heile
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1233782T3 publication Critical patent/DK1233782T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00993586T 1999-12-01 2000-12-01 Fremkaldelse af HCV-specifikke antistoffer DK1233782T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US18505500P 2000-02-25 2000-02-25
PCT/US2000/042541 WO2001047551A2 (en) 1999-12-01 2000-12-01 Eliciting antibodies specific for hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
DK1233782T3 true DK1233782T3 (da) 2009-02-09

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00993586T DK1233782T3 (da) 1999-12-01 2000-12-01 Fremkaldelse af HCV-specifikke antistoffer

Country Status (12)

Country Link
US (3) US7329408B2 (da)
EP (1) EP1233782B1 (da)
JP (1) JP2004500366A (da)
AT (1) ATE413190T1 (da)
AU (1) AU5442501A (da)
CA (1) CA2393251C (da)
CY (1) CY1108734T1 (da)
DE (1) DE60040755D1 (da)
DK (1) DK1233782T3 (da)
ES (1) ES2319727T3 (da)
PT (1) PT1233782E (da)
WO (1) WO2001047551A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
ES2319727T3 (es) * 1999-12-01 2009-05-12 Novartis Vaccines And Diagnostics, Inc. Estimulacion de anticuerpos especificos de hcv.
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
CA2451739A1 (en) * 2001-06-29 2003-01-09 Chiron Corporation Hcv e1e2 vaccine compositions
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
EP1585542B1 (en) * 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
WO2004065578A2 (en) * 2003-01-14 2004-08-05 Chiron Corporation Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
US20040203084A1 (en) * 2003-04-10 2004-10-14 Doug Levinson Profiling conformational variants, antibody compositions and methods of using the same
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
US9107831B2 (en) * 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
RU2006144714A (ru) * 2004-05-17 2008-06-27 Чирон Корпорейшн (Us) Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки
DK1765310T3 (da) 2004-05-28 2016-01-11 Oryxe Blanding til transdermal afgivelse af lav- og højmolekylvægtforbindelser
CA2578021C (en) 2004-08-24 2014-11-18 Tokyo Metropolitan Organization For Medical Research Modified human hepatitis c virus genomic rna that can be autonomously replicated
KR100959456B1 (ko) * 2004-11-18 2010-05-25 고쿠리츠다이가쿠호진 히로시마다이가쿠 유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
EP2177535A4 (en) 2007-07-25 2010-08-25 Jp Nat Inst Infectious Disease ANTIBODIES HAVING INHIBITORY ACTIVITY ON HEPATITIS C VIRUS INFECTION (HCV) AND USE THEREOF
JP5756757B2 (ja) 2009-10-30 2015-07-29 東レ株式会社 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体及びその用途
AU2011334543B2 (en) * 2010-11-26 2015-05-21 The Macfarlane Burnet Institute For Medical Research And Public Health Compositions and methods
JP6736464B2 (ja) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
WO2017048807A1 (en) 2015-09-17 2017-03-23 Jrx Biotechnology, Inc. Approaches for improving skin hydration or moisturization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
ES2316920T3 (es) 1994-07-29 2009-04-16 Novartis Vaccines And Diagnostics, Inc. Popipeptido truncado e2 de hepatitis c y procedimientos para obtener el mismo.
PT773957E (pt) * 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
EP0862419B2 (en) * 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
JP4458556B2 (ja) 1997-05-06 2010-04-28 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃ型肝炎のｅ２短縮型ポリペプチドの細胞内生成
WO1999004010A1 (en) * 1997-07-18 1999-01-28 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
ES2319727T3 (es) * 1999-12-01 2009-05-12 Novartis Vaccines And Diagnostics, Inc. Estimulacion de anticuerpos especificos de hcv.

Also Published As

Publication number Publication date
CA2393251C (en) 2012-01-31
EP1233782A2 (en) 2002-08-28
CY1108734T1 (el) 2014-04-09
WO2001047551A3 (en) 2002-03-14
US20110159039A1 (en) 2011-06-30
ES2319727T3 (es) 2009-05-12
US7329408B2 (en) 2008-02-12
PT1233782E (pt) 2009-02-13
EP1233782B1 (en) 2008-11-05
US20020002272A1 (en) 2002-01-03
CA2393251A1 (en) 2001-07-05
AU5442501A (en) 2001-07-09
US20080095800A1 (en) 2008-04-24
WO2001047551A2 (en) 2001-07-05
JP2004500366A (ja) 2004-01-08
DE60040755D1 (de) 2008-12-18
ATE413190T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
DK0693687T4 (da) Kombinationer af hepatitis C-virus (HCV)-antigener til anvendelse i immunoassays for anti-HCV-antistoffer
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
NO20051715L (no) HCV assay
DK0643838T3 (da) Fremgangsmåde til påvisning af antistoffer hos seronegative individer
RU2008114385A (ru) ИНДУКТОР СЕКРЕТОРНЫХ АНТИТЕЛ IgA И IgG
DK1230932T3 (da) Anvendelse af antistoffer til vaccinering mod cancer
ATE478681T1 (de) Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
WO2003040341A3 (en) Anti-hepatitis a virus antibodies
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
WO2001093804A3 (en) Hepatitis c virus conjugates
DE69227776D1 (de) Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE60142836D1 (de) Nicht menschliche tiermodelle die toleranz gegenüber hepatitis c virus immunogene aufweisen
WO2003014728A1 (fr) Medicaments contre l'hepatite c